Phil Tsai
About Phil Tsai
Philip Tsai, Ph.D. is Immunome’s Chief Technical Officer, age 57, and joined the company in June 2024. He previously spent 21 years in technical leadership roles, most recently serving as Senior Vice President of Technical Development at Seagen (May 2021–April 2024), and earlier optimizing biologics manufacturing processes at Biogen for seven years. Dr. Tsai holds an M.S. and Ph.D. in Chemical Engineering from the California Institute of Technology and a B.S. from the University of Illinois, Urbana-Champaign . The 2025 proxy does not present TSR, revenue, or EBITDA performance metrics tied to Dr. Tsai’s compensation; he was not a Named Executive Officer (NEO) for 2024 .
Past Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| Seagen | Senior Vice President, Technical Development | May 2021–Apr 2024 | Led technical development for biologics; senior responsibility across development operations |
| Biogen | Technical roles in biologics manufacturing | ~7 years | Optimized biologics manufacturing processes, driving scale-up and process efficiency |
External Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| — | — | — | None disclosed in the proxy statement |
Equity Ownership & Alignment
- Insider trading policy prohibits hedging and pledging by directors, officers, employees, certain consultants and their designees .
- Clawback/recoupment of incentive compensation is overseen by the Compensation Committee .
- Equity programs in place: 2020 Equity Incentive Plan (options/RSUs), ESPP, assumed Morphimmune 2020 plan, and a 2024 Inducement Plan for new hires (no repricing allowed without shareholder approval) .
| Ownership Metric | Value |
|---|---|
| Common shares held (direct/beneficial) | 21,000 |
| Options (exercisable/unexercisable) | Not disclosed for Dr. Tsai in the 2025 proxy |
| Shares outstanding (reference) | 86,796,919 as of Feb 1, 2025 |
| Pledging/Hedging status | Pledging and hedging prohibited by policy |
Note: Form 4 insider trading data could not be retrieved programmatically at time of analysis; update when available to assess any open market purchases/sales and award activity.
Employment Terms
- Start date and role: Chief Technical Officer since June 2024 .
- Employment agreement details (salary, bonus targets, severance, change-in-control) for Dr. Tsai are not disclosed in the 2025 proxy; the Employment Agreements section covers the CEO, CBO, and Chief Legal Officer only .
- Non-compete/non-solicit/garden leave terms: Not disclosed for Dr. Tsai in the proxy .
- Grant timing and vesting practices (company-wide context): Initial grants typically have a one-year cliff and then monthly vesting over the next three years; annual refresh grants typically vest monthly over four years and are now timed to the third-quarter Compensation Committee meeting cycle .
Investment Implications
- Alignment: Direct ownership of 21,000 shares combined with a corporate prohibition on hedging/pledging supports baseline alignment; further visibility into his option/RSU holdings would strengthen the skin-in-the-game analysis .
- Retention/vesting levers: Company practices rely on time-based option vesting (one-year cliff, then monthly), which is a retention mechanism; the 2024 Inducement Plan provides a vehicle for new-hire equity, suggesting potential ongoing equity incentives for Dr. Tsai given his June 2024 start .
- Compensation transparency: As a non-NEO in 2024, Dr. Tsai’s individual cash/equity targets, performance metrics, and severance/change-of-control terms are not disclosed; monitor future proxies for NEO status or disclosure updates and Form 4 filings for grant/transaction activity .
- Execution profile: Dr. Tsai’s tenure leading Technical Development at Seagen and prior Biogen manufacturing optimization background indicates deep process and scale-up expertise critical for Immunome’s development and manufacturing execution .